Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVAHNASDAQ:MGNXNASDAQ:PSNLNASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVAHAveanna Healthcare$4.91-7.7%$4.78$2.11▼$6.19$961.81M2.25246,772 shs153,620 shsMGNXMacroGenics$1.06-8.1%$2.36$1.05▼$19.54$67.19M2.121.17 million shs468,117 shsPSNLPersonalis$3.08-6.7%$4.44$1.14▼$7.20$273.62M1.89941,958 shs568,516 shsVRDNViridian Therapeutics$11.70-7.5%$16.31$11.40▼$27.20$948.97M1.051.17 million shs554,015 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVAHAveanna Healthcare-5.34%-3.62%+33.33%+14.16%+112.80%MGNXMacroGenics-5.74%-22.30%-50.43%-66.76%-91.59%PSNLPersonalis-7.30%-7.82%-19.71%-50.30%+144.44%VRDNViridian Therapeutics-3.21%-13.77%-16.94%-37.35%-22.20%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVAHAveanna Healthcare0.6966 of 5 stars1.02.00.00.03.32.50.0MGNXMacroGenics3.7234 of 5 stars3.22.00.04.41.52.50.6PSNLPersonalis4.0904 of 5 stars3.52.00.04.23.22.50.6VRDNViridian Therapeutics1.188 of 5 stars3.41.00.00.02.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVAHAveanna Healthcare 2.00Hold$4.940.52% UpsideMGNXMacroGenics 2.36Hold$7.38597.73% UpsidePSNLPersonalis 3.00Buy$7.80153.25% UpsideVRDNViridian Therapeutics 2.75Moderate Buy$35.70205.08% UpsideCurrent Analyst Ratings BreakdownLatest PSNL, MGNX, VRDN, and AVAH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025MGNXMacroGenicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $2.003/17/2025PSNLPersonalisCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.003/14/2025AVAHAveanna HealthcareUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSell ➝ Sell$3.20 ➝ $4.502/28/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.002/28/2025PSNLPersonalisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.25 ➝ $7.001/27/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.001/8/2025PSNLPersonalisLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $9.001/8/2025PSNLPersonalisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.25 ➝ $7.251/8/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.001/7/2025VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.001/6/2025AVAHAveanna HealthcareTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$6.00 ➝ $5.25(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVAHAveanna Healthcare$2.02B0.47$0.67 per share7.34($0.68) per share-7.22MGNXMacroGenics$148.34M0.45N/AN/A$2.46 per share0.43PSNLPersonalis$84.61M3.21N/AN/A$2.64 per share1.17VRDNViridian Therapeutics$302K3,157.41N/AN/A$4.48 per share2.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVAHAveanna Healthcare-$134.52M-$0.07N/A∞N/A-3.32%N/A-0.89%5/8/2025 (Estimated)MGNXMacroGenics-$9.06M-$1.08N/AN/AN/A-69.07%-89.42%-38.57%5/8/2025 (Estimated)PSNLPersonalis-$108.30M-$1.37N/AN/AN/A-104.52%-66.07%-41.34%5/6/2025 (Estimated)VRDNViridian Therapeutics-$237.73M-$3.77N/AN/AN/A-85,127.16%-70.12%-41.49%5/6/2025 (Estimated)Latest PSNL, MGNX, VRDN, and AVAH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2025Q4 2024MGNXMacroGenics-$0.23-$0.25-$0.02-$0.25$34.17 million$49.40 million2/27/2025Q4 2024PSNLPersonalis-$0.32-$0.23+$0.09-$0.23$15.48 million$16.80 million2/27/2025Q4 2024VRDNViridian Therapeutics-$1.05-$0.81+$0.24-$0.81$0.05 million$0.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVAHAveanna HealthcareN/AN/AN/AN/AN/AMGNXMacroGenicsN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVAHAveanna HealthcareN/A0.940.94MGNXMacroGenicsN/A3.753.69PSNLPersonalisN/A4.684.44VRDNViridian Therapeutics0.0418.5518.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVAHAveanna Healthcare87.96%MGNXMacroGenics96.89%PSNLPersonalis61.91%VRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAVAHAveanna Healthcare7.80%MGNXMacroGenics11.30%PSNLPersonalis4.10%VRDNViridian Therapeutics0.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVAHAveanna Healthcare33,000195.09 million178.15 millionOptionableMGNXMacroGenics43063.09 million55.67 millionOptionablePSNLPersonalis40088.26 million67.75 millionOptionableVRDNViridian Therapeutics5081.49 million78.70 millionOptionablePSNL, MGNX, VRDN, and AVAH HeadlinesRecent News About These Companies25,000 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Bought by Knott David M JrApril 2 at 7:26 AM | marketbeat.comPictet Asset Management Holding SA Boosts Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)April 2 at 4:31 AM | marketbeat.comLoomis Sayles & Co. L P Acquires New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)March 29, 2025 | marketbeat.comBIT Capital GmbH Increases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)March 28, 2025 | marketbeat.comRaymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN)March 25, 2025 | marketbeat.comCommit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using OptionsMarch 22, 2025 | nasdaq.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Yiheng Capital Management L.P.March 22, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)March 22, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from AnalystsMarch 20, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Bank of New York Mellon CorpMarch 19, 2025 | marketbeat.com410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc.March 15, 2025 | marketbeat.comViridian Therapeutics appoints new director, sees board resignationMarch 12, 2025 | investing.comCandriam S.C.A. Has $14.02 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)March 7, 2025 | marketbeat.comResearch Analysts Issue Forecasts for VRDN Q1 EarningsMarch 6, 2025 | marketbeat.comFisher Asset Management LLC Acquires 23,103 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)March 5, 2025 | marketbeat.comQ2 Earnings Forecast for VRDN Issued By B. RileyMarch 4, 2025 | marketbeat.comViridian Therapeutics Faces Uncertainty Amid Regulatory Approval ChallengesMarch 4, 2025 | tipranks.comViridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year WindowMarch 2, 2025 | seekingalpha.comViridian Therapeutics Reports Strong Progress and FinancialsFebruary 28, 2025 | tipranks.comViridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue EstimatesFebruary 27, 2025 | zacks.comViridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSNL, MGNX, VRDN, and AVAH Company DescriptionsAveanna Healthcare NASDAQ:AVAH$4.91 -0.41 (-7.67%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and employer of record support and personal care services, as well as in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.MacroGenics NASDAQ:MGNX$1.06 -0.09 (-8.09%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Personalis NASDAQ:PSNL$3.08 -0.22 (-6.67%) As of 12:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Viridian Therapeutics NASDAQ:VRDN$11.70 -0.95 (-7.49%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
